As he battled acute myeloid leukaemia (AML) with intense chemotherapy, his body weight fell to 40 kg. Now he’s built his body back, weighs 75 kg and inspires other cancer survivors to reclaim their lives
Aiming to overcome the obstacles that have stalled the utilization of T-cell immunotherapies in acute myeloid leukemia, two research teams have concurrently found a promising solution in one protein target along with the potential to expand into solid tumors.
Kura Oncology is back in the game. Two months after the FDA sidelined its blood cancer trial in response to a patient death, Kura has had the partial clinical hold lifted, clearing it to resume the screening and enrollment of new patients.